Imagine a child, their joy dimmed by the constant ache of arthritis, or the debilitating grip of multiple sclerosis. But there's hope! The Pharmaceutical Benefits Scheme (PBS) in Australia is expanding its reach, offering crucial support to those battling chronic illnesses. This means more affordable access to life-changing medications.
Newly listed medicines on the PBS are set to benefit young Australians with arthritis and those suffering from rare conditions like liver disease and multiple sclerosis. These additions aim to alleviate the financial burden and provide access to vital treatments.
One key addition is Adalimumab (Humira®), now expanded to treat juvenile idiopathic arthritis, along with other pediatric immune-mediated inflammatory diseases (IMIDs) such as Crohn’s disease, ulcerative colitis, and chronic plaque psoriasis. These IMIDs cause painful inflammation, which can hinder growth and lead to long-term disabilities. Humira works by calming the immune system, helping children regain mobility and enjoy a better quality of life. It's estimated that between 18,500 to 30,100 Australians aged 0 to 24 are affected by arthritis.
But here's where it gets controversial... Without the PBS subsidy, families could face exorbitant costs. Health Minister Mark Butler highlights that without the subsidy, patients could pay around $650 per script. However, with the PBS, the cost is significantly reduced to a maximum of $25 per script, or just $7.70 for concession card holders. This is a massive difference! The government is committed to strengthening the PBS by adding the latest treatments recommended by experts.
Other significant additions to the PBS include:
- Odevixibat (Bylvay®): Listed for the first time to treat progressive familial intrahepatic cholestasis (PFIC), a rare genetic liver disease. PFIC causes a build-up of bile acids, leading to severe itching and liver damage. It's estimated to affect between 1 in 50,000 and 1 in 100,000 live births globally. Without the subsidy, families could pay over $200,000 per script. Bylvay reduces bile acid levels, improving the quality of life for patients.
- Ublituximab (Briumvi®): Also a first-time listing, for the treatment of relapsing-remitting multiple sclerosis (RRMS). This autoimmune disease damages the central nervous system. Briumvi targets the B-cells that drive inflammation, helping to reduce relapses and slow disease progression. In 2024, over 14,000 patients accessed a comparable treatment through the PBS. Without the subsidy, patients might pay $15,000 per script.
The PBS is part of the Australian Government’s National Medicines Policy, ensuring access to essential medications. It began in 1948 as a limited scheme, offering free medicines to pensioners and a list of 139 “life-saving and disease-preventing” medicines. Today, the PBS includes over 900 medicines, covering more than 5,000 different brands. The PBS Schedule lists all government-subsidized medicines, managed by the Department of Health, Disability and Ageing and administered by Services Australia.
What do you think? Are these changes enough? Do you have experience with any of these conditions, or have you benefited from the PBS? Share your thoughts in the comments below! Is there a need for further expansion of the PBS to include more medications or to reduce costs further?
